Filter Search for grants
Call Navigation
Call key data
Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential
Funding Program | Horizon Europe - Cluster 1 - Destination 3: Tackling diseases and reducing disease burden | |
Call number | HORIZON-HLTH-2023-DISEASE-03-04 | |
deadlines | Opening 12.01.2023 | Deadline 13.04.2023 17:00 |
Funding rate | 100% | |
Call budget | € 50,000,000.00 | |
Estimated EU contribution per project | between € 7,000,000.00 and € 8,000,000.00 | |
Link to the call | ec.europa.eu | |
Link to the submission | ec.europa.eu |
Call content
short description | Proposals should develop and advance broad-spectrum anti-viral compounds and develop novel approaches to the development of such compounds, which target viruses with high epidemic or pandemic potential for the EU, such as those included in the list of priority diseases of the World Health Organization (WHO), with particular attention to those meeting the criteria identified by the Health Emergency Preparedness and Response Authority (HERA). |
Call objectives | As shown by the COVID-19 pandemic, infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is expected to accelerate due to among other, climate change, and thus a proactive approach to the development of anti-viral therapeutics in preparedness for future infectious disease outbreaks is needed. The availability of broad-spectrum anti-viral therapies would provide a critical preparedness measure against future health threats, due to infectious disease epidemics or pandemics. Proposals should cover viruses for which there are no currently available effective therapeutics or for which the therapeutics available are sub-optimal, and are expected to incorporate state-of-the-art screening technology and innovative approaches to identify new targets for antiviral compound development. Emphasis should be put on the research and development of broad-spectrum antivirals, which may include repurposing of previously approved or in-pipeline drugs. Proposals could also include elucidation of mode-of-action for candidate anti-viral therapeutics. Proposals should aim to diversify and accelerate the global therapeutic research and development pipeline for emerging and re-emerging viral infections, and to strengthen the current leading role of the EU in therapeutic research and development. Proposals should address all of the following areas:
Applicants are expected to engage with regulatory bodies in a timely manner to ensure adequacy of the actions from a regulatory point of view. Applicants envisaging to include clinical studies should provide details of their clinical studies in the dedicated annex using the template provided in the submission system. See definition of clinical studies in the introduction to this work programme part. read more |
Expected effects and impacts | |
Expected results |
|
Regions / countries for funding | EU Member States, Overseas Countries and Territories (OCT) Moldova (Moldova), Albania (Shqipëria), Armenia (Հայաստան), Bosnia and Herzegovina (Bosna i Hercegovina / Босна и Херцеговина), Faeroes (Føroyar / Færøerne), Georgia (საქართველო), Island (Ísland), Israel (ישראל / إِسْرَائِيل), Kosovo (Kosova/Kosovë / Косово), Montenegro (Црна Гора), Morocco (المغرب), North Macedonia (Северна Македонија), Norway (Norge), Serbia (Srbija/Сpбија), Tunisia (تونس /Tūnis), Türkiye, Ukraine (Україна), United Kingdom |
eligible entities | EU Body, Education and training institution, International organization, Natural Person, Non-Profit Organisation (NPO) / Non-Governmental Organisation (NGO), Other, Private institution, incl. private company (private for profit), Public Body (national, regional and local; incl. EGTCs), Research Institution incl. University, Small and medium-sized enterprise (SME) |
Mandatory partnership | Yes |
Project Partnership | To be eligible for funding, applicants must be established in one of the following countries:
Applications may be submitted by one or more legal entities, which may be established in a Member State, Associated Country or, in exceptional cases and if provided for in the specific call conditions, in another third country. In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding. Any legal entity, regardless of its place of establishment, including legal entities from non-associated third countries or international organisations (including international European research organisations) is eligible to participate (whether it is eligible for funding or not), provided that the conditions laid down in the Horizon Europe Regulation have been met, along with any other conditions laid down in the specific call topic. A ‘legal entity’ means any natural or legal person created and recognised as such under national law, EU law or international law, which has legal personality and which may, acting in its own name, exercise rights and be subject to obligations, or an entity without legal personality. Specific cases:
|
Additional information
Topics |
Disaster Prevention, Resilience, Risk Management, Health, Social Services, Sports |
Relevance for EU Macro-Region | EUSAIR - EU Strategy for the Adriatic and Ionian Region, EUSALP - EU Strategy for the Alpine Space, EUSBSR - EU Strategy for the Baltic Sea Region, EUSDR - EU Strategy for the Danube Region |
UN Sustainable Development Goals (UN-SDGs) |
![]() |
Additional Information | All proposals must be submitted electronically via the Funders & Tenders Portal electronic submission system (accessible via the topic page in the Search Funding & Tenders section). Paper submissions are NOT possible. Proposals must be complete and contain all parts and mandatory annexes and supporting documents, e.g. plan for the exploitation and dissemination of the results including communication activities, etc. The application form will have two parts:
Annexes and supporting documents will be directly available in the submission system and must be uploaded as PDF files (or other formats allowed by the system). The limit for a full application (Part B) is 45 pages. The award criteria are described in General Annex D. The following exceptions apply: The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12. |
Call documents | HE-Work Programme 2023-2024, Cluster 1, Destination 3 (556kB) |
Contact | National Contact Points for Horizon Europe Website |
To see more information about this call, you can register for free here
or log in with an existing account.
Log in
Register now